Patient Portal

Sysmex is active in a broad spectrum of healthcare areas. In addtion
to information for healthcare professionals we also provide 
applied information for privat individuals seeking assistance in our
areas of expertise. 

At the moment we provide guidance and background info on
breast cancer. We welcome you to visit http://www.breast-cancer-diagnosis.co.uk/

 

 

Please select your country. This will keep you up to date with your country-specific information.

OncoBEAM™

  • Highly sensitive liquid biopsy
  • Reliable guidance for selecting cancer patients’ therapy
  • No more waiting. Comprehensive and rapid analysis before or during therapy

Documents

All
  • All
  • Brochure
Documents

Therapy is only as good as its diagnostics

Every cancer is different and standardised treatment based on chemotherapy is not always effective. Therefore, targeted therapy has to be applied. Yet its application depends on the mutational status of certain genes of a cancer patient. Precision diagnostics are the key to selecting patients eligible for targeted therapy. Here, liquid biopsy has become a valuable tool for analyzing decisive mutations. It allows you to select the initial targeted therapy as well as monitor your patient’s response to treatment or the emergence of resistance.

OncoBEAM™ is an established liquid biopsy technology based on cell-free DNA from blood. Its unparalleled sensitivity is the key to optimising therapy selection and monitoring the mutational status during therapy or in recurrent cases where tumor burden might be low. OncoBEAM’s clinical value has been demonstrated in various studies and over 30 Centres of Excellence worldwide use OncoBEAM™ in routine diagnostics.

BEAMing Digital PCR technology combines emulsion PCR with magnetic beads and flow cytometry for the highly sensitive detection and quantification of mutant tumour DNA molecules.

 

OncoBEAM – Highly sensitive Liquid Biopsy for Transforming Clinical Care

  • Viable alternative to tissue testing due to its high concordance (>90%) with tissue biopsy
  • Reliable detection of alterations that occur at low mutant allele frequencies (MAF) as 0.01%
  • Support for the timely and non-invasive analysis of relevant mutations before, during or after targeted therapy.

Oncology

Video: Beaming Digital PCR

Video: Beaming Digital PCR

OncoBEAM RAS CRC IVD

OncoBEAM RAS CRC IVD

The OncoBEAM™ RAS CRC IVD analyses 34 clinically relevant RAS mutations as recommended by international guidelines. It is widely used for selecting mCRC patients eligible for anti-EGFR therapy and can be used for monitoring thanks to its high sensitivity.

OncoBEAM EGFR (RUO)

OncoBEAM EGFR (RUO)

The OncoBEAM™ EGFR (RUO) test enables the highly sensitive analysis of 10 EGFR mutations, including T790M and C797S. These mutations play an important role in Non-Small-Cell-Lung-Cancer (NSCLC) and can lead either to resistance or sensitisation towards the different lines of anti-EGFR therapy.

Video: Carmen’s story

Video: Carmen’s story

Publications

Publications

Please see our publication list

Contact

Alexandra Kurz
Product Manager

kurz.alexandra@sysmex-europe.com
Bornbarch 1
22848 Norderstedt

Create Pdf
Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
Explore our microsite
See our collection